Surprisingly! US FDA Delays Approval of Eli Lilly's New Drug for Alzheimer's Disease: US pharmaceutical giant Eli Lilly announced on Friday that the US Food and Drug Administration (FDA) has unexpectedly delayed its approval decision for its new Alzheimer's drug dononemab and will convene an external expert meeting to discuss the safety and efficacy of its drug. Affected by this news, the stock price of Lilly fell nearly 2% during trading.